Share on StockTwits
 

Sequenom (NASDAQ:SQNM) will be releasing its Q214 earnings data on Tuesday, July 29th. Analysts expect Sequenom to post earnings of ($0.10) per share and revenue of $47.80 million for the quarter.

Sequenom (NASDAQ:SQNM) last released its earnings data on Thursday, May 1st. The company reported ($0.13) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.14) by $0.01. The company had revenue of $46.30 million for the quarter, compared to the consensus estimate of $46.06 million. During the same quarter in the prior year, the company posted ($0.26) earnings per share. The company’s quarterly revenue was up 20.3% on a year-over-year basis. On average, analysts expect Sequenom to post $-0.35 EPS for the current fiscal year and $-0.02 EPS for the next fiscal year.

Sequenom (NASDAQ:SQNM) opened at 3.67 on Monday. Sequenom has a 52-week low of $1.65 and a 52-week high of $4.17. The stock’s 50-day moving average is $3.61 and its 200-day moving average is $2.80. The company’s market cap is $427.2 million.

SQNM has been the subject of a number of recent research reports. Analysts at Jefferies Group initiated coverage on shares of Sequenom in a research note on Thursday, July 3rd. They set a “buy” rating and a $5.00 price target on the stock. On a related note, analysts at William Blair upgraded shares of Sequenom from a “market perform” rating to an “outperform” rating in a research note on Monday, June 23rd. Finally, analysts at Wedbush raised their price target on shares of Sequenom to $5.00 in a research note on Tuesday, June 17th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Sequenom presently has an average rating of “Buy” and an average price target of $5.33.

Sequenom, Inc (NASDAQ:SQNM) is a molecular diagnostic testing and genetics analysis company committed to providing molecular diagnostic testing services, and research use only products, services, applications, and genetic analysis products that translate the results of genomic science into solutions for biomedical research, translational research, molecular medicine applications, and agricultural, livestock, and other areas of research.

Stay on top of analysts' upgrades and downgrades with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' ratings changes. Register Now.